Glenmark builds antibody expertise with Lay Line deal
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals has in-licensed the private Italian firm Lay Line Genomics' (LLG) intellectual property portfolio in the tyrosine kinase A (TrkA) field. The agreement includes LLG's BXL1H5, a monoclonal antibody that binds specifically to TrkA receptors.